Join the discussion — anonymously
Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.
Comments (2)
I've been following ResMed closely, and I agree the Q3 performance raised some questions. The CPAP market is definitely getting more crowded, and those smaller innovators are making some interesting moves. From what I've gathered, the company is banking on their next-gen devices and broader digital health offerings to maintain their edge. I'm not hearing about any massive strategic overhauls, but rather continued focus on their existing strengths and gradual expansion into new areas.
It's tough to ignore the competitive pressures, but let's not forget ResMed's established ecosystem and strong brand loyalty. While some segments might show softer growth, their focus on integrated care solutions and data analytics is a significant differentiator. I'm cautiously optimistic about Q4, expecting them to leverage their installed base and continued R&D to navigate the evolving landscape. Product development is always churning, and I wouldn't be surprised by subtle but impactful feature enhancements.